FrancophonIA/ELRC3.0 huggingface dataset:
English: Hetlioz contains the active substance tasimelteon.
Estonian: Hetlioz sisaldab toimeainena tasimelteooni.
English: Because the number of patients with non-24-hour sleep-wake disorder is low, the disease is considered ‘rare', and Hetlioz was designated an ‘orphan medicine' (a medicine used in rare diseases) on 23 February 2011.
Estonian: Et mitte-24-tunnise une- ja ärkveloleku häirega patsientide arv on väike ja see haigus esineb harva, nimetati Hetlioz 23. veebruaril 2011 harvikravimiks.
English: Hetlioz is available as 20 mg capsules and can only be obtained with a prescription.
Estonian: Hetlioz on retseptiravim ja seda turustatakse kapslitena (20 mg).
English: What benefits of Hetlioz have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Hetliozi kasulikkus?
English: Of the 10 patients who remained on Hetlioz, 9 people remained adjusted to 24-hour clock at the end of the study, compared with 2 of the 10 patients who were switched to placebo.
Estonian: 10 patsiendist, kellele anti jätkuvalt Hetliozi, säilis uuringu lõpuks 9 inimesel kohastumus 24-tunnise tsükliga, võrreldes 2 patsiendiga 10-st, kes said platseebot.
English: Hetlioz has been shown to be effective at helping patients adjust to the standard 24-hour clock in 2 main studies.
Estonian: Kahest põhiuuringust nähtus, et Hetlioz aitab patsientidel efektiivselt kohaneda tavalise 24-tunnise tsükliga.
English: A hormone called melatonin plays a key role in co-ordinating the body's sleep-wake cycle.
Estonian: Organismi une-ärkveloleku tsükli koordineerimises mängib põhirolli hormoon melatoniin.
English: How does Hetlioz work?
Estonian: Kuidas Hetlioz toimib?
English: How is Hetlioz used?
Estonian: Kuidas Hetliozi kasutatakse?
English: It must also not be used in the following groups:
Estonian: Samuti ei tohi seda kasutada järgmised patsiendirühmad:
English: This summary was last updated in 01-2012.
Estonian: Kokkuvõtte viimane uuendus: 01-2012.
English: Teysuno capsules are taken with water at least one hour before or after a meal.
Estonian: Teysuno kapsleid võetakse koos veega vähemalt üks tund enne või pärast sööki.
English: The full EPAR for Teysuno can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Teysuno kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The recommended dose for one cycle of treatment is 25 mg/m2 twice a day (in the morning and evening) for three weeks, followed by a one-week rest period.
Estonian: Soovitatav annus üheks ravitsükliks on 25 mg/m2 kaks korda ööpäevas (hommikul ja õhtul) kolme nädala jooksul, millele järgneb ühenädalane puhkeaeg.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Teysuno on 14 March 2011.
Estonian: Euroopa Komisjon andis Teysuno müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 14. märtsil
English: The main measure of effectiveness was how long the patients lived.
Estonian: Efektiivsuse põhinäitaja oli patsiendi elulemus.
English: Other information about Teysuno
Estonian: Muu teave Teysuno kohta
English: Teysuno tegafur/gimeracil/oteracil
Estonian: Teysuno tegafuur/gimeratsiil/oteratsiil
English: The CHMP decided that Teysuno's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Teysuno kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Treatment with Teysuno capsules was as effective as treatment with 5-FU infusions.
Estonian: Ravi Teysuno kapslitega oli sama efektiivne kui ravi 5-FU infusioonidega.
English: It is available as capsules containing 15 mg tegafur with 4.35 mg gimeracil and 11.8 mg oteracil, and as capsules containing 20 mg tegafur with 5.8 mg gimeracil and 15.8 mg oteracil.
Estonian: Ravimit turustatakse kapslitena, mis sisaldavad 15 mg tegafuuri, 4,35 mg gimeratsiili ja 11,8 mg oteratsiili, ning kapslitena, mis sisaldavad 20 mg tegafuuri, 5,8 mg gimeratsiili ja 15,8 mg oteratsiili.
English: What is Teysuno?
Estonian: Mis on Teysuno?
English: • patients with severe kidney problems requiring dialysis;
Estonian: • tõsiste neeruprobleemidega patsiendid, kes vajavad dialüüsi;
English: 5-FU is similar to pyrimidine, a substance found in the genetic material of cells (DNA and RNA).
Estonian: 5-FU sarnaneb pürimidiinile, mida leidub rakkude geneetilises materjalis (DNAs ja RNAs).
English: The cycle is repeated every four weeks, including once cisplatin administration is stopped after six cycles.
Estonian: Ravitsüklit korratakse iga nelja nädala tagant, ka pärast tsisplatiini manustamise lõpetamist kuue ravitsükli järel.
English: This is a summary of the European public assessment report (EPAR) for Teysuno.
Estonian: See on ravimi Teysuno Euroopa avaliku hindamisaruande kokkuvõte.
English: Teysuno is a medicine that contains the active substances tegafur, gimeracil and oteracil.
Estonian: Teysuno on ravim, mis sisaldab toimeainena tegafuuri, gimeratsiili ja oteratsiili.
English: • pregnant or breast-feeding women;
Estonian: • rasedad ja imetavad patsiendid;
English: The dose to be taken is calculated based on the active substance tegafur and the patient's body surface area (calculated using the patient's height and weight).
Estonian: Teysuno annus arvutatakse toimeaine tegafuuri ja patsiendi kehapindala (arvutatakse patsiendi pikkuse ja kaalu järgi) alusel.
English: • patients with a deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD) as well as patients who, within the previous four weeks, have been treated with a medicine that inhibits this enzyme;
Estonian: • ensüüm dihüdropürimidiindehüdrogenaasi puudulikkusega patsiendid ja patsiendid, keda eelneva nelja nädala vältel on ravitud selle ensüümi aktiivsust pärssiva ravimiga;
English: • patients who should not be receiving cisplatin.
Estonian: • patsiendid, keda ei tohi ravida tsisplatiiniga.
English: Why has Teysuno been approved?
Estonian: Miks Teysuno heaks kiideti?
English: Both medicines were given with cisplatin.
Estonian: Mõlemat ravimit manustati koos tsisplatiiniga.
English: Tegafur is a ‘prodrug' that is converted in the body to a chemical called 5-fluorouracil (5-FU).
Estonian: Tegafuur on eelravim, mis muudetakse organismis keemiliseks aineks 5-fluorouratsiiliks (5-FU).
English: What is the risk associated with Teysuno?
Estonian: Mis riskid Teysunoga kaasnevad?
English: Teysuno must not be used in people who are hypersensitive (allergic) to any of the active substances or any of the other ingredients.
Estonian: Teysunot ei tohi kasutada patsiendid, kes on toimeaine või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Teysuno.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For the full list of all side effects reported with Teysuno, see the package leaflet.
Estonian: Teysuno kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The two other active substances in Teysuno allow tegafur to be effective at lower doses and with fewer side effects: gimeracil by preventing the breakdown of 5-FU and oteracil by reducing the activity of 5FU in normal, non-cancerous tissue in the gut.
Estonian: Kaks ülejäänud Teysuno toimeainet muudavad tegafuuri toimivaks väiksemate annuste puhul ja vähemate kõrvalnähtudega: gimeratsiil takistab 5-FU lagundamist organismis ja oteratsiil vähendab 5FU toimet soole normaalsele kasvajavabale koele.
English: Teysuno should only be prescribed by a qualified doctor experienced in treating cancer patients with anticancer medicines.
Estonian: Teysunot tohib välja kirjutada üksnes vähipatsientide ravis ja vähiravimite kasutamises kogenud arst.
English: For more information about treatment with Teysuno, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Teysunoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In the body, 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA.
Estonian: 5-FU asendab organismis pürimidiini ja häirib uue DNA moodustamises osalevate ensüümide toimet.
English: As a result, it prevents the growth of cancer cells and eventually kills them.
Estonian: Selle tulemusena pärsib 5-FU kasvajarakkude kasvu ja lõpuks hävitab need.
English: For more information on the use of Teysuno, including how to use it with cisplatin, see the summary of product characteristics (also part of the EPAR).
Estonian: Lisateave Teysuno kasutamise kohta, sealhulgas selle kohta, kuidas seda kasutada koos tsisplatiiniga, on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: In patients treated with Teysuno in combination with cisplatin, the most common severe side effects (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, a type of white blood cell), anaemia (low red blood cell counts) and fatigue (tiredness).
Estonian: Teysuno ja tsisplatiini kombinatsiooniga ravitud patsientide hulgas olid kõige sagedamad tõsised kõrvalnähud (esinenud enam kui 1 patsiendil 10st) neutropeenia (neutrofiilide ehk teatud valgeliblede vähesus), aneemia (punaliblede vähesus) ja väsimus.
English: In the main study, Teysuno was compared with the anticancer medicine 5-FU given as an infusion in 1,053 adults with advanced gastric cancer.
Estonian: Põhiuuringus võrreldi Teysunot vähiravimiga 5-FU, mida manustati infusioonina 1053-le kaugelearenenud maovähiga täiskasvanud patsiendile.
English: The main active substance in Teysuno, tegafur, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the ‘anti-metabolites' group.
Estonian: Teysuno toimeaine tegafuur on antimetaboliitide hulka kuuluv tsütotoksiline aine (ravim, mis hävitab poolduvaid rakke, näiteks vähirakke).
English: • patients with severe leucopenia, neutropenia, or thrombocytopenia (low levels of white cells or platelets in the blood);
Estonian: • patsiendid, kellel on raske leukopeenia, neutropeenia või trombotsütopeenia (vastavalt valgeliblede, teatud valgeliblede neutrofiilide või teatud valgeliblede trombotsüütide väike sisaldus veres);
English: It is used in combination with cisplatin (another anticancer medicine).
Estonian: Teysunot kasutatakse koos tsisplatiiniga (samuti vähiravim).
English: What benefit has Teysuno shown during the studies?
Estonian: Milles seisneb uuringute põhjal Teysuno kasulikkus?
English: Patients receiving Teysuno with cisplatin lived for an average of 8.6 months compared with 7.9 months for patients receiving 5-FU with cisplatin.
Estonian: Patsiendid, kes said Teysunot koos tsisplatiiniga, elasid keskmiselt 8,6 kuud.
English: How is Teysuno used?
Estonian: Kuidas Teysunot kasutatakse?
English: • patients currently receiving another fluoropyrimidine (a group of anticancer medicines that includes
Estonian: • patsiendid, kes saavad samal ajal ravi mõne teise fluoropürimidiiniga (vähiravimite rühm, kuhu kuulub Teysuno) või kellel on esinenud raskeid ja ootamatuid reaktsioone fluoropürimidiinidele;
English: Teysuno is used together with cisplatin, in a 4-week cycle starting on the day of the cisplatin administration.
Estonian: Teysunot kasutatakse koos tsisplatiiniga neljanädalaste ravitsüklitena.
English: How has Teysuno been studied?
Estonian: Kuidas Teysunot uuriti?
English: How does Teysuno work?
Estonian: Kuidas Teysuno toimib?
English: What is Teysuno used for?
Estonian: Milleks Teysunot kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Teysuno on retseptiravim.
English: Teysuno is used to treat adults with advanced gastric (stomach) cancer.
Estonian: Teysunot kasutatakse kaugelearenenud maovähi raviks täiskasvanud patsientidel.
English: (periodontal 2008)
Estonian: (periodontaalne 2008)
English: (2003 survey)
Estonian: (2003 uuring)
English: ITALY
Estonian: ITAALIA
English: Allergic reactions to these substances may occasionally be serious.
Estonian: Allergilised reaktsioonid nendele ainetele võivad olla väga ägedad.
English: The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
Estonian: Müügiloa hoidja peab informeerima Euroopa Komisjoni selle otsusega heaks kiidetud ravimpreparaadi turustamisplaanidest.
English: ATCvet code: QJ01DD91.
Estonian: ATCvet kood: QJ01DD91
English: Store in a refrigerator (2 °C - 8 °C).
Estonian: Hoida külmkapis (2 °C - 8 °C).
English: Treated animals should not be used for breeding for 12 weeks after the last administration.
Estonian: Ravitud loomi ei tohiks aretuses kasutada 12 nädala jooksul pärast viimast manustamist.
English: Elimination half-life is long - approximately 6.9 days.
Estonian: Eliminatsiooni poolväärtusaeg on pikk - umbes 6,9 päeva.
English: Do not use in dogs and cats less than 8 weeks old.
Estonian: Mitte kasutada noorematel kui 8 nädala vanustel koertel ja kassidel.
English: Pyoderma is often secondary to an underlying disease.
Estonian: Püoderma on sageli sekundaarne haigus.
English: For the full list of excipients, see section 6.1.
Estonian: Abiainete täielik loetelu on esitatud lõigus 6.1.
English: If required, treatment may be repeated at 14 day intervals up to a further three times.
Estonian: Vajadusel võib ravi korrata 14 päevase intervalliga veel kuni kolm korda.
English: The antimicrobial activity of Convenia following a single injection lasts for up to 14 days.
Estonian: Convenia antimikroobne toime pärast üht süsti kestab kuni 14 päeva.
English: The fundamental requirement of the treatment of periodontal disease is mechanical and/or surgical intervention by the veterinarian.
Estonian: Põhitingimus periodontaalhaiguse raviks on mehaaniline ja/või kirurgiline veterinaarne sekkumine.
English: Do not use in small herbivores (including guinea pigs and rabbits).
Estonian: Mitte kasutada väikestel herbivooridel (sealhulgas meriseal ja küülikul).
English: After reconstitution, use within 28 days.
Estonian: Pärast lahuse valmistamist kasutada ära 28 päeva jooksul.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/06/2006
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 19.06.2006
English: Elimination half-life is long - approximately 5.5 days.
Estonian: Poolväärtusaeg on pikk - umbes 5,5 päeva.
English: Store in the original package in order to protect from light (before and after reconstitution).
Estonian: Hoida originaalpakendis valguse eest kaitstult (enne ja pärast lahustamist).
English: In the event of contact, wash skin with soap and water.
Estonian: Kokkupuute korral pesta nahka seebi ja veega.
English: (e.g. S. xylosus, S. schleiferi, S. epidermidis) is 9.5 %.
Estonian: S. xylosus, S. schleiferi, S. epidermidis) on 9,5 %.
English: Periodontal isolates were collected during a European (France and Belgium) clinical efficacy and safety field study (2008).
Estonian: Periodontaalisolaate koguti Euroopas läbi viidud (Prantsusmaa ja Belgia) kliinilise efektiivsuse ja ohutuse väliuuringul (2008).
English: Date of last renewal: 15/06/2011
Estonian: Müügiloa viimase uuendamise kuupäev: 15.06.2011
English: It is, therefore, advisable to determine the underlying cause and to treat the animal accordingly.
Estonian: Selle tõttu on soovitatav kindlaks teha esmane haigus ja ravida looma vastavalt.
English: CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Estonian: TARNIMIS- JA KASUTAMISTINGIMUSED VÕI PIIRANGUD
English: Resistance may be chromosomal or plasmid-encoded and may be transferred if associated with transposons or plasmids.
Estonian: Resistentsus võib olla kromosoomiline või plasmiidkodeeritud ja võib üle kanduda transposoonide või plasmiidide vahendusel.
English: Dog Cat Pasteurella multocida Dog Cat
Estonian: Koer Kass Pasteurella multocida Koer Kass
English: ADVICE ON CORRECT ADMINISTRATION
Estonian: SOOVITUSED ÕIGE MANUSTAMISE OSAS
English: Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
Estonian: Näo, huulte või silmade turse või hingamisraskused on raskemad sümptomid ja nõuavad viivitamatut arstiabi.
English: Store in the original package in order to protect from light.
Estonian: Hoida originaalpakendis valguse eest kaitstult.
English: The safety of Convenia in dogs and cats has not been established during pregnancy and lactation.
Estonian: Convenia ohutus koertele ja kassidele tiinuse ja laktatsiooni perioodil ei ole tõestatud.
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Estonian: Sobivusuuringute puudumisel ei tohi seda veterinaarravimit segada teiste veterinaarravimitega.
English: As with other cephalosporins, the colour of the reconstituted solution may darken during this period.
Estonian: Nagu ka teiste tsefalosopriinide puhul, võib valmisahuse värvus selle perioodi jooksul tumeneda.
English: Handle this product with care to avoid exposure, taking all recommended precautions.
Estonian: Kokkupuutest hoidumiseks käsitseda seda preparaati ettevaatlikult, rakendades kõiki soovitatud ettevaatusabinõusid.
English: Veterinarians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.
Estonian: Veterinaarid peavad teadvustama, et allergilised reaktsioonid võivad pärast sümptomaatilise ravi lõpetamist taasilmuda.
English: MANUFACTURER'S BATCH NUMBER Lot: {number}
Estonian: TOOTJAPOOLNE PARTII NUMBER Lot {number}
English: Do not use this veterinary medicinal product after the expiry date which is stated on the carton.
Estonian: Ärge kasutage veterinaarravimit pärast kõlblikkusaega, mis on märgitud karbil.
English: Plasma protein binding is high (more than 99 %) and the volume of distribution is low (0.09 l/kg).
Estonian: Seondumine plasmaproteiiniga on kõrge (rohkem kui 99 %) ja jaotusruumala madal (0,09 l/kg).
English: Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies.
Estonian: Preparaaadi kasutaminee peab põhinema tundlikkustestil ning tuleb arvestada kohalikku ametlikku antimikrobiaalse ravi poliitikat.
English: Pharmacotherapeutic group: Antibacterials for systemic use (cephalosporins).
Estonian: Farmakoterapeutiline rühm: Antibakteriaalsed ained süsteemseks kasutamiseks (tsefalosopriinid).
English: In very rare cases neurological signs and injection site reactions have been reported after the use of the product.
Estonian: Väga harvadel juhtudel on pärast preparaadi kasutamist ilmnenud neuroloogilisi nähte ja süstekoha reaktsioone.
English: EXP: {mm/yyyy}
Estonian: EXP {kuu/aasta}
English: Active substance:
Estonian: Toimeained:
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt http://www.ema.europa.eu/.
English: Plasma protein binding is high (96.0 % to 98.7 %) and the volume of distribution is low (0.1 l/kg).
Estonian: Seondumine plasmaproteiiniga on kõrge (96,0 % kuni 98,7 %) ja jaotusruumala madal (0,1 l/kg).
English: For use only for the following infections requiring prolonged treatment.
Estonian: Kasutada ainult järgnevate pikaajalist ravi vajavate infektsioonide raviks.
English: A single administration of 22.5 times the recommended dose caused transient oedema and discomfort at the injection site.
Estonian: Ühekordne manustamine 22,5-kordses soovitatavas doosis põhjustas mööduva turse ja ebamugavustunde süstekohal.
English: On very rare occasions gastrointestinal signs, including emesis and/or diarrhoea, have been observed.
Estonian: Väga harvadel juhtudel on täheldatud gastrointestinaalsete häirete esinemist nagu oksendamine ja/või diarröa.
English: However, if stored as recommended, potency is not affected.
Estonian: Kui lahust säilitatakse vastavalt soovitustele, siis see lahuse tugevust ei mõjuta.
English: DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Estonian: PAKENDI INFOLEHE VIIMASE KOOSKÕLASTAMISE KUUPÄEV Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt http://www.ema.europa.eu/.
English: If you know you are allergic to penicillins or cephalosporins, avoid contact with contaminated litter.
Estonian: Kui olete allergiline penitsilliinidele või tsefalosporiinidele, vältige kontakti preparaadi jäätmematerjaliga.
English: THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” Keep out of the sight and reach of children.
Estonian: MÄRGE ”HOIDA LASTE EEST VARJATUD JA KÄTTESAAMATUS KOHAS” Hoida laste eest varjatud ja kättesaamatus kohas.
English: When applying a proposed microbiological breakpoint of I ≤ 4 µg/ml, cefovecin resistance in S. pseudintermedius and beta-haemolytic Streptococci isolates was less than 0.02 % and 3.4 % in Prevotella intermedia isolates.
Estonian: Soovitava mikrobioloogilise murdepunkti I≤4 µg/ml rakendamisel oli tsefovetsiini resistentsus S. pseudointermedius'e ja beeta-hemolüütiliste streptokokkide isolaatidel alla 0,02 % ning Prevotella intermedia isolaatidel 3,4 %.
English: Pseudomonas spp., Enterococcus spp., and Bordetella bronchiseptica isolates are inherently resistant to cefovecin.
Estonian: Pseudomonas spp., Enterococcus spp, ja Bordetella bronchiseptica isolaadid omavad loomulikku resistentsust tsefovetsiinile.
English: Disposal: read package leaflet.
Estonian: Hävitamine: vt pakendi infolehte.
English: The powder is off-white to yellow and the diluent (solvent) is a clear, colourless liquid.
Estonian: Pulber on valkjat kuni kollast värvi ja diluent (lahusti) on selge värvitu vedelik.
English: In accordance with good veterinary practice, treatment of pyoderma should be extended beyond complete resolution of clinical signs.
Estonian: Vastavalt heale loomaarstlikule tavale peaks püoderma ravi jätkama ka pärast kliiniliste nähtude täielikku kadumist.
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) Each vial contains 852 mg cefovecin.
Estonian: TOIMEAINE(TE) KOGUS Iga viaal sisaldab 852 mg tsefovetsiini.
English: S.S. 156 Km 47,600 04100 Borgo San Michele Latina
Estonian: Haupt Pharma Latina S.r.l S.S. 156 Km 47,600 04100 Borgo San Michele Latina
English: If required, an additional dose may be administered 14 days after the first injection.
Estonian: Vajadusel võib ravi korrata 14 päeva pärast esimest manustamist.
English: BATCH NUMBER Lot: {number}
Estonian: PARTII NUMBER Lot {number}
English: SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use.
Estonian: ERIHOIATUS(ED), KUI VAJALIK Enne ravimi kasutamist lugege pakendi infolehte.
English: Resistance to cephalosporins results from enzymatic inactivation (β-lactamase production) or from other mechanisms.
Estonian: Resistentsus tsefalosporiinidele tuleneb ensümaatilisest inaktiveerimisest (beeta-laktamaasi tootmine) või teistest mehhanismidest.
English: Special precautions for use in animals
Estonian: Ettevaatusabinõud kasutamisel loomadel
English: Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporins and vice versa.
Estonian: Ülitundlikkus penitsilliinidele võib põhjustada ristreaktsioone tsefalosporiinidega ja vastupidi.